Anti-Diabetic Retinopathy Molecular Mechanism of Dihuang Yinzi: Insights from Network Pharmacology, Metabolomics, and Microbiome Analysis - Summary - MDSpire

Anti-Diabetic Retinopathy Molecular Mechanism of Dihuang Yinzi: Insights from Network Pharmacology, Metabolomics, and Microbiome Analysis

  • By

  • Chai, Jinmiao

  • Gui, Wanwei

  • Zhang, Junlong

  • He, Wenbin

  • Li, Qinqing

  • April 28, 2026

  • 0 min

Share

Objective:

To clarify essential target genes, metabolic entities, and microbial organisms involved in the therapeutic efficacy of Dihuang Yinzi (DHYZ) against diabetic retinopathy (DR).

Key Findings:
  • Identified 110 candidate genes and five primary target genes: STAT3, IL6, TNF, ESR1, and IL1B.
  • Molecular docking revealed strong binding interactions, particularly between ESR1 and naringenin.
  • Metabolomic assessment identified 50 candidate metabolites.
  • Microbiome evaluation uncovered 24 candidate microbes.
  • Spearman correlation analysis identified 30 key metabolites and 18 key microbes.
Interpretation:

The study elucidates the multi-omics mechanisms through which DHYZ may exert its therapeutic effects in managing diabetic retinopathy.

Limitations:
  • The study was conducted on a murine model, which may not fully replicate human conditions.
  • Sample size was limited to eighteen subjects, potentially affecting the generalizability of findings.
Conclusion:

This investigation provides critical insights into the mechanisms of DHYZ in DR management, identifying key genes, metabolites, and microbes involved.

Original Source(s)

Anti-Diabetic Retinopathy Molecular Mechanism of Dihuang Yinzi: Insights from Network Pharmacology, Metabolomics, and Microbiome Analysis

  • by Chai, Jinmiao , Gui, Wanwei , Zhang, Junlong , He, Wenbin , Li, Qinqing

  • April 28, 2026

Related Content

Assessment of Two-Phase Diagnostic Timelines in Diabetic Retinopathy and Contributing Factors: A Cross-Sectional Analysis

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

New Strategies for Managing Diabetic Retinopathy